Phase 3 trial testing on severely ill COVID-19 patients has reached 50 per cent enrolment Mesoblast expects to complete enrolment … Read More
The post Mesoblast has treated dozen of COVID-19 patients with its remestemcel-L drug appeared first on Stockhead.
Barry Stroman was a reporter for Zerg Watch, before becoming the lead editor. Barry has previously worked for Wired, MacWorld, PCWorld, and VentureBeat covering countless stories concerning all things related to tech and science. Barry studied at NYU.